About Satsuma Pharmaceuticals, Inc.
We are a clinical-stage biopharmaceutical company dedicated to bringing novel treatments to people who suffer from migraine and other debilitating conditions. Our initial product candidate is STS101 (dihydroergotamine (DHE) nasal powder), which we are focused on developing as an important and differentiated therapeutic option for the acute treatment of migraine
|
|
|
11-50 employees
View all Satsuma Pharmaceuticals, Inc. employees
|
|
Pharmaceuticals
|
|
$10M–$50M
|
|
(858) 550-1000
|
|
395 Oyster Point Boulevard, Suite 300, South San Francisco, CA 94080, US
|
|
2016
|
Satsuma Pharmaceuticals, Inc. Alternatives
Frequently Asked Questions about Satsuma Pharmaceuticals, Inc.
John Kollins is the CEO of Satsuma Pharmaceuticals, Inc.. To contact John Kollins email at [email protected].
The decision makers in Satsuma Pharmaceuticals, Inc. are Cindy Zhong, Dave Prichard, Diana Sayre, etc. Click to Find Satsuma Pharmaceuticals, Inc. decision makers emails.
Satsuma Pharmaceuticals, Inc. headquarters is located at 395 Oyster Point Boulevard, Suite 300, South San Francisco, CA 94080, US.
Satsuma Pharmaceuticals, Inc. generates an estimated $10M–$50M annually, based on industry analysis and publicly available market data.
You can contact Satsuma Pharmaceuticals, Inc. by calling (858) 550-1000.
Satsuma Pharmaceuticals, Inc. Staff Directory
Search Satsuma Pharmaceuticals, Inc. Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.
